Skip to main content
Top

Breast Cancer

Issue 4/2009

Content (17 Articles)

Conference Paper

From standardization to personalization in breast cancer treatment

Shinzaburo Noguchi, Masakazu Toi

Conference Paper

Breast cancer risk assessment for possible tailored screening for Japanese women

Yasuhiro Tamaki, Yasuyuki Kotsuma, Yasuo Miyoshi, Shinzaburo Noguchi

Conference Paper

Clinicopathological characteristics of triple-negative breast cancers

Yuka Sasaki, Hitoshi Tsuda

Conference Paper

Clinical significance of basal-like subtype in triple-negative breast cancer

Yutaka Yamamoto, Mutsuko Ibusuki, Masahiro Nakano, Teru Kawasoe, Ryousuke Hiki, Hirotaka Iwase

Conference Paper

Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction

Tomohiko Ohta, Wenwen Wu, Ayaka Koike, Hideki Asakawa, Hirotaka Koizumi, Mamoru Fukuda

Special Feature

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

Yutaka Tokuda, Yasuhiro Suzuki, Yuki Saito, Shinobu Umemura

Original Article

Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

Masahiko Tanabe, Yoshinori Ito, Nahomi Tokudome, Tsutomu Sugihara, Hiroyoshi Miura, Shunji Takahashi, Yasuyuki Seto, Takuji Iwase, Kiyohiko Hatake

Original Article

A cluster of microcalcifications: women with high risk for breast cancer versus other women

Takayoshi Uematsu, Masako Kasami, Sachiko Yuen

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine